1. Stotz M., Liegl-Atzwanger B., Posch F. et al. Blood-based biomarkers are associated with disease recurrence and survival in gastrointestinal stroma tumor patients after surgical resection // PLoS One. 2016. Vol. 11. № 7. P. e0159448.
2. Kirkwood J.M., Richards T., Zarour H.M. et al. Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690 // Cancer. 2002. Vol. 95. № 5. P. 1101–1112.
3. Mano R., Flynn J., Blum K.A. et al. The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma // Urol. Oncol. 2019. Vol. 37. № 12. P. 916–923.
4. Neal C.P., Cairns V., Jones M.J. et al. Prognostic performance of inflammation-based prognostic indices in patients with resectable colorectal liver metastases // Med. Oncol. 2015. Vol. 32. № 5. P. 144.
5. Eo W., Kim H.B., Lee Y.J. et al. Preoperative lymphocyte-monocyte ratio is a predictor of suboptimal cytoreduction in stage III–IV epithelial ovarian cancer // J. Cancer. 2016. Vol. 7. № 13. P. 1772–1779.
6. Yi M., Jiao D., Xu H. et al. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors // Mol. Cancer. 2018. Vol. 17. № 1. P. 129.
7. Foulds G.A., Vadakekolathu J., Abdel-Fatah T.M.A. et al. Immune-phenotyping and transcriptomic profiling of peripheral blood mononuclear cells from patients with breast cancer: identification of a 3 gene signature which predicts relapse of triple negative breast cancer // Front. Immunol. 2018. Vol. 9. ID 2028.
8. Masucci G.V., Cesano A., Hawtin R. et al. Validation of biomarkers to predict response to immunotherapy in cancer: volume I – pre-analytical and analytical validation // J. Immunother. Cancer. 2016. Vol. 4. ID 76.
9. Стахеева М.Н., Чердынцева Н.В. Взаимосвязь эффективной цитостатической терапии с соcтоянием иммунной системы у больных злокачественными новообразованиями // Исследования и практика в медицине. 2018. Т. 5. № S2. С. 267.
10. Кадагидзе З.Г., Заботина Т.Н., Короткова О.В. и др. Влияние ипилимумаба на субпопуляционную структуру лимфоцитов больных диссеминированной меланомой // Практическая онкология. 2017. Т. 18. № 3. С. 285–297.
11. Shimura T., Toiyama Y., Saigusa S. et al. Inflammation-based prognostic scores as indicators to select candidates for primary site resection followed by multimodal therapy among colorectal cancer patients with multiple metastases // Int. J. Clin. Oncol. 2017. Vol. 22. № 4. P. 758–766.
12. Hodek M., Sirak I., Ferko A. et al. Neoadjuvant chemoradiotherapy of rectal carcinoma: baseline hematologic parameters influencing outcomes // Strahlenther. Onkol. 2016. Vol. 192. № 9. P. 632–640.
13. Liao R., Tang Z.W., Li D.W. et al. Preoperative neutrophil-to-lymphocyte ratio predicts recurrence of patients with single-nodule small hepatocellular carcinoma following curative resection: a retrospective report // World J. Surg. Oncol. 2015. Vol. 13. ID 265.
14. Zhang J., Chen L., Zhou R. et al. Pretreatment lymphocyte monocyte ratio predicts long-term outcomes in patients with digestive system tumor: a meta-analysis // Gastroenterol. Res. Pract. 2016.
15. Tham T., Olson C., Khaymovich J. et al. The lymphocyte-to-monocyte ratio as a prognostic indicator in head and neck cancer: a systematic review and meta-analysis // Eur. Arch. Otorhinolaryngol. 2018. Vol. 275. № 7. P. 1663–1670.
16. Guo Y.H., Sun H.F., Zhang Y.B. et al. The clinical use of the platelet/lymphocyte ratio and lymphocyte/monocyte ratio as prognostic predictors in colorectal cancer: a meta-analysis // Oncotarget. 2017. Vol. 8. № 12. P. 20011–20024.
17. Peng H., Luo X. Prognostic significance of elevated pretreatment systemic inflammatory markers for patients with prostate cancer: a meta-analysis // Cancer Cell Int. 2019. Vol. 19. ID 70.
18. Wang D.P., Kang K., Lin Q. et al. Prognostic significance of preoperative systemic cellular inflammatory markers in gliomas: a systematic review and meta-analysis // Clin. Transl. Sci. 2019.
19. Saied A., Licata L., Burga R.A. et al. Neutrophil:lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor-modified T-cell infusions for liver metastases // Cancer Gene Ther. 2014. Vol. 21. № 11. P. 457–462.
20. Reich R.R., Lengacher C.A., Kip K.E. et al. Baseline immune biomarkers as predictors of MBSR(BC) treatment success in off-treatment breast cancer patients // Biol. Res. Nurs. 2014. Vol. 16. № 4. P. 429–437.
21. Kimyon Comert G., Turkmen O., Kar I. et al. Independent predictors of survival in endometrium cancer: platelet-to-lymphocyte ratio and platelet/neutrophil/monocyte-to-lymphocyte ratio // J. Turk. Ger. Gynecol. Assoc. 2018. Vol. 19. № 2. P. 78–86.
22. Peng Y., Chen R., Qu F. et al. Low pretreatment lymphocyte/monocyte ratio is associated with the better efficacy of neoadjuvant chemotherapy in breast cancer patients // Cancer Biol. Ther. 2020. Vol. 21. № 2. P. 189–196.
23. Luo P., Cai W., Yang L. et al. Prognostic significance of pretreatment lymphocyte/monocyte ratio in retroperitoneal liposarcoma patients after radical resection // Cancer Manag. Res. 2018. Vol. 10. P. 4727–4734.
24. Dolan R.D., Lim J., McSorley S.T. et al. The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: systematic review and meta-analysis // Sci. Rep. 2017. Vol. 7. № 1. P. 16717.
25. Quillien V., Carpentier A.F., Gey A. et al. Absolute numbers of regulatory T cells and neutrophils in corticosteroid-free patients are predictive for response to bevacizumab in recurrent glioblastoma patients // Cancer Immunol. Immunother. 2019. Vol. 68. № 6. P. 871–882.
26. Maltoni M., Pirovano M., Nanni O. et al. Biological indices predictive of survival in 519 Italian terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care // J. Pain Symptom Manage. 1997. Vol. 13. № 1. P. 1–9.
27. Vardy J.L., Dhillon H.M., Pond G.R. et al. Prognostic indices of inflammatory markers, cognitive function and fatigue for survival in patients with localised colorectal cancer // ESMO Open. 2018. Vol. 3. № 2. P. e000302.
28. Савченко А.А., Лапешин П.В., Дыхно Ю.А. Состояние иммунной системы и метаболизм здоровых и опухолевых клеток легочной ткани у больных немелкоклеточным раком легкого в зависимости от метастазирования // Российский биотерапевтический журнал. 2005. Т. 4. № 2. С. 106–112.
29. Sears H.F., Simon R., Rosenberg S.A. Longitudinal studies of cellular immunity of patients with osteogenic sarcoma during chemoimmunotherapy // Cancer Treat. Rep. 1980. Vol. 64. № 4–5. P. 589–597.
30. Millrud C.R., Mansson Kvarnhammar A., Uddman R. et al. The activation pattern of blood leukocytes in head and neck squamous cell carcinoma is correlated to survival // PLoS One. 2012. Vol. 7. № 12. P. e51120.
31. Витковский Ю.А., Ильиных Л.В., Кузник Б.И. и др. Состояние иммунитета и лимфоцитарно-тромбоцитарной адгезии при раке гортани // Медицинская иммунология. 2007. Т. 9. № 6. P. 653–659.
32. Кухарев Я.В., Стахеева М.Н., Дорошенко А.В. и др. Связь иммунологических показателей с эффективностью неоадъювантной химиотерапии у больных раком молочной железы // Сибирский онкологический журнал. 2013. № 2. С. 50–57.
33. Webster D.J., Richardson G., Baum M. et al. Effect of treatment on the immunological status of women with advanced breast cancer // Br. J. Cancer. 1979. Vol. 39. № 6. P. 676–680.
34. Qi Q., Geng Y., Sun M. et al. Clinical implications of systemic inflammatory response markers as independent prognostic factors for advanced pancreatic cancer // Pancreatology. 2015. Vol. 15. № 2. P. 145–150.
35. Yokota M., Katoh H., Nishimiya H. et al. Lymphocyte-monocyte ratio significantly predicts recurrence in papillary thyroid cancer // J. Surg. Res. 2020. Vol. 246. P. 535–543.
36. Eo W.K., Kwon S., Koh S.B. et al. The lymphocyte-monocyte ratio predicts patient survival and aggressiveness of endometrial cancer // J. Cancer. 2016. Vol. 7. № 5. P. 538–545.
37. Jan C.I., Tsai W.C., Harn H.J. et al. Predictors of response to autologous dendritic cell therapy in glioblastoma multiforme // Front. Immunol. 2018. Vol. 9. ID 727.
38. Szkandera J., Gerger A., Liegl-Atzwanger B. et al. The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas // Int. J. Cancer. 2014. Vol. 135. № 2. P. 362–370.
39. Новик А.В., Проценко С.А., Балдуева И.А. и др. Оценка состояния иммунной системы у больных, получавших первую линию химиотерапии метастатической меланомы кожи в исследовании МММ-1 // Сб. тезисов V Петербургского международного онкологического форума «Белые ночи 2019». 2019. С. 121.
40. Hu P., Shen H., Wang G. et al. Prognostic significance of systemic inflammation-based lymphocyte-monocyte ratio in patients with lung cancer: based on a large cohort study // PLoS One. 2014. Vol. 9. № 9. P. e108062.
41. Mitchell P., Thatcher N., Socinski M.A. et al. Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses // Ann. Oncol. 2015. Vol. 26. № 6. P. 1134–1142.
42. Савченко А.А., Дыхно Ю.А., Лапешин П.В. Зависимость состояния иммунного статуса и метаболизма лимфоцитов от метастазирования при немелкоклеточном раке легкого // Медицинская иммунология. 2009. Т. 11. № 4–5. С. 434.
43. Sharaiha R.Z., Halazun K.J., Mirza F. et al. Elevated preoperative neutrophil:lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer // Ann. Surg. Oncol. 2011. Vol. 18. № 12. P. 3362–3369.
44. Liu X., Li M., Zhao F. et al. The lymphocyte-monocyte ratio predicts tumor response and survival in patients with locally advanced esophageal cancer who received definitive chemoradiotherapy // Onco Targets Ther. 2017. Vol. 10. P. 871–877.
45. Bentdal O.H., Froland S.S., Bosnes V. et al. Alterations in lymphocyte subsets in blood may predict resectability in carcinoma of cardia or oesophagus // Cancer Lett. 1996. Vol. 100. № 1–2. P. 133–138.
46. Fox P., Hudson M., Brown C. et al. Markers of systemic inflammation predict survival in patients with advanced renal cell cancer // Br. J. Cancer. 2013. Vol. 109. № 1. P. 147–153.
47. Неродо Г.А., Златник Е.Ю., Закора Г.И. и др. Некоторые показатели состояния иммунного статуса у больных раком вульвы // Современные проблемы науки и образования. 2012. № 3. С. 60–66.
48. Ong H.S., Gokavarapu S., Wang L.Z. et al. Low pretreatment lymphocyte-monocyte ratio and high platelet-lymphocyte ratio indicate poor cancer outcome in early tongue cancer // J. Oral. Maxillofac. Surg. 2017. Vol. 75. № 8. P. 1762–1774.
49. Стахеева М.Н., Чойнзонов Е.Л., Чижевская С.Ю. и др. Взаимосвязь эффективности противоопухолевого лечения с состоянием иммунной системы у больных раком гортани и гортаноглотки // Медицинская иммунология. 2013. Т. 15. № 6. С. 553–562.
50. Соловьева И.Г., Егоров Д.Н., Вардосанидзе К.В. и др. Параметры иммунитета у больных раком желудка // Вопросы онкологии. 2006. Т. 52. № 3. С. 305–308.
51. Казакова Н.Н., Савченко А.А., Яцинов М.В. Особенности состояния иммунного статуса в зависимости от стадии рака желудка // Медицинская иммунология. 2009. Т. 11. № 4–5. С. 429.
52. Cho U., Park H.S., Im S.Y. et al. Prognostic value of systemic inflammatory markers and development of a nomogram in breast cancer // PLoS One. 2018. Vol. 13. № 7. P. e0200936.
53. Nicolini A., Rossi G., Ferrari P. et al. Clinical and laboratory patterns during immune stimulation in hormone responsive metastatic breast cancer // Biomed. Pharmacother. 2014. Vol. 68. № 2. P. 171–178.
54. Santegoets S.J., Stam A.G., Lougheed S.M. et al. T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment // Cancer Immunol. Immunother. 2013. Vol. 62. № 2. P. 245–256.
55. Eo W.K., Chang H.J., Kwon S.H. et al. The lymphocyte-monocyte ratio predicts patient survival and aggressiveness of ovarian cancer // J. Cancer. 2016. Vol. 7. № 3. P. 289–296.
56. Tang T., Liao R., Li J. et al. Analysis of prognostic factors of patients with hepatocellular carcinoma after radical resection // Zhonghua Wai Ke Za Zhi. 2016. Vol. 54. № 6. P. 439–443.
57. Shen Y., Wang H., Li W. et al. Prognostic significance of the CRP/Alb and neutrophil to lymphocyte ratios in hepatocellular carcinoma patients undergoing TACE and RFA // J. Clin. Lab. Anal. 2019. Vol. 33. № 9. P. e22999.
58. Nishijima T.F., Deal A.M., Lund J.L. et al. Inflammatory markers and overall survival in older adults with cancer // J. Geriatr. Oncol. 2019. Vol. 10. № 2. P. 279–284.
59. Patel M., McSorley S.T., Park J.H. et al. The relationship between right-sided tumour location, tumour microenvironment, systemic inflammation, adjuvant therapy and survival in patients undergoing surgery for colon and rectal cancer // Br. J. Cancer. 2018. Vol. 118. № 5. P. 705–712.
60. Dolan R.D., McSorley S.T., Park J.H. et al. The prognostic value of systemic inflammation in patients undergoing surgery for colon cancer: comparison of composite ratios and cumulative scores // Br. J. Cancer. 2018. Vol. 119. № 1. P. 40–51.
61. Wang Y.Y., Liu Z.Z., Xu D. et al. Fibrinogen-Albumin Ratio Index (FARI): a more promising inflammation-based prognostic marker for patients undergoing hepatectomy for colorectal liver metastases // Ann. Surg. Oncol. 2019. Vol. 26. № 11. P. 3682–3692.
62. Bai X., Feng L. Correlation between Prognostic Nutritional Index, Glasgow Prognostic Score, Systemic Inflammatory Response, and TNM Staging in colorectal cancer patients // Nutr. Cancer. 2019. Vol. 1. ID 8.
63. Deng Y.X., Lin J.Z., Peng J.H. et al. Lymphocyte-to-monocyte ratio before chemoradiotherapy represents a prognostic predictor for locally advanced rectal cancer // Onco Targets Ther. 2017. Vol. 10. P. 5575–5583.
64. Climent M., Ryan E.J., Stakelum A. et al. Systemic inflammatory response predicts oncological outcomes in patients undergoing elective surgery for mismatch repair-deficient colorectal cancer // Int. J. Colorectal. Dis. 2019. Vol. 34. № 6. P. 1069–1078.
65. Ichikawa N., Homma S., Yoshida T. et al. An increase in the peripheral lymphocyte-to-monocyte ratio after primary site resection is associated with a prolonged survival in unresectable colorectal carcinoma // Surg. Today. 2019.
66. Matsuda A., Yamada T., Matsumoto S. et al. Pretreatment neutrophil-to-lymphocyte ratio predicts survival after TAS-102 treatment of patients with metastatic colorectal cancer // Anticancer Res. 2019. Vol. 39. № 8. P. 4343–4350.
67. Iacono D., Basile D., Gerratana L. et al. Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma // Melanoma Res. 2019. Vol. 29. № 5. P. 510–515.
68. Leontovich A.A., Dronca R.S., Nevala W.K. et al. Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients // Melanoma Res. 2017. Vol. 27. № 1. P. 32–42.
69. Li Y.J., Yang X., Zhang W.B. et al. Clinical implications of six inflammatory biomarkers as prognostic indicators in Ewing sarcoma // Cancer Manag. Res. 2017. Vol. 9. P. 443–451.
70. Wang Y., Chen G. Identifying pretreatment baseline factors predictive of distant metastasis in patients with nasopharyngeal carcinoma after radiotherapy // Medicine (Baltimore). 2017. Vol. 96. № 17. P. e6692.
71. Liang H.G., Gao K., Jia R. et al. Prognostic significance of the combination of preoperative fibrinogen and the neutrophil-lymphocyte ratio in patients with non-small cell lung cancer following surgical resection // Oncol. Lett. 2019. Vol. 17. № 2. P. 1435–1444.
72. Luo H., Ge H., Cui Y. et al. Systemic inflammation biomarkers predict survival in patients of early stage non-small cell lung cancer treated with stereotactic ablative radiotherapy – a single center experience // J. Cancer. 2018. Vol. 9. № 1. P. 182–188.
73. Liu B., Huang Y., Sun Y. et al. Prognostic value of inflammation-based scores in patients with osteosarcoma // Sci. Rep. 2016. Vol. 6. ID 39862.
74. Liu J.S., Huang Y., Yang X. et al. A nomogram to predict prognostic values of various inflammatory biomarkers in patients with esophageal squamous cell carcinoma // Am. J. Cancer Res. 2015. Vol. 5. № 7. P. 2180–2189.
75. Han L.H., Jia Y.B., Song Q.X. et al. Prognostic significance of preoperative lymphocyte-monocyte ratio in patients with resectable esophageal squamous cell carcinoma // Asian Pac. J. Cancer Prev. 2015. Vol. 16. № 6. P. 2245–2250.
76. Wang C., Zhao K., Huang Y. et al. Baseline FDG uptake and peripheral lymphocyte-monocyte ratio for predicting chemoradiotherapy response in patients with esophageal squamous cell carcinoma // Cancer Manag. Res. 2019. Vol. 11. P. 9085–9093.
77. Dai Y., Fu X., Li T. et al. Long-term impact of prognostic nutritional index in cervical esophageal squamous cell carcinoma patients undergoing definitive radiotherapy // Ann. Transl. Med. 2019. Vol. 7. № 8. P. 175.
78. Hutterer G.C., Stoeckigt C., Stojakovic T. et al. Low preoperative lymphocyte-monocyte ratio (LMR) represents a potentially poor prognostic factor in nonmetastatic clear cell renal cell carcinoma // Urol. Oncol. 2014. Vol. 32. № 7. P. 1041–1048.
79. Yamamoto Y., Matsuyama H., Matsumoto H. et al. Prognostic value of risk stratification using blood parameters for nivolumab in Japanese patients with metastatic renal-cell carcinoma // Jpn. J. Clin. Oncol. 2019.
80. Tham T., Wotman M., Chung C. et al. Systemic immune response in squamous cell carcinoma of the head and neck: a comparative concordance index analysis // Eur. Arch. Otorhinolaryngol. 2019. Vol. 276. № 10. P. 2913–2922.
81. Chen L., Zhang F., Sheng X.G. et al. Decreased pretreatment lymphocyte/monocyte ratio is associated with poor prognosis in stage Ib1-IIa cervical cancer patients who undergo radical surgery // Onco Targets Ther. 2015. Vol. 8. P. 1355–1362.
82. Zhou T., Yu S.T., Chen W.Z. et al. Pretreatment albumin globulin ratio has a superior prognostic value in laryngeal squamous cell carcinoma patients: a comparison study // J. Cancer. 2019. Vol. 10. № 3. P. 594–601.
83. Lin J.X., Lin J.P., Xie J.W. et al. Prognostic value and association of sarcopenia and systemic inflammation for patients with gastric cancer following radical gastrectomy // Oncologist. 2019. Vol. 24. № 11. P. e1091–e1101.
84. Sato B., Kanda M., Tanaka C. et al. Significance of preoperative systemic inflammation score in short-term and long-term outcomes of patients with pathological T2–4 gastric cancer after radical gastrectomy // World J. Surg. 2018. Vol. 42. № 10. P. 3277–3285.
85. Lee K.H., Kim E.Y., Yun J.S. et al. The prognostic and predictive value of tumor-infiltrating lymphocytes and hematologic parameters in patients with breast cancer // BMC Cancer. 2018. Vol. 18. № 1. P. 938.
86. Losada B., Guerra J.A., Malon D. et al. Pretreatment neutrophil/lymphocyte, platelet/lymphocyte, lymphocyte/monocyte, and neutrophil/monocyte ratios and outcome in elderly breast cancer patients // Clin. Transl. Oncol. 2019. Vol. 21. № 7. P. 855–863.
87. Sierzega M., Lenart M., Rutkowska M. et al. Preoperative neutrophil-lymphocyte and lymphocyte-monocyte ratios reflect immune cell population rearrangement in resectable pancreatic cancer // Ann. Surg. Oncol. 2017. Vol. 24. № 3. P. 808–815.
88. Yu S.L., Xu L.T., Qi Q. et al. Serum lactate dehydrogenase predicts prognosis and correlates with systemic inflammatory response in patients with advanced pancreatic cancer after gemcitabine-based chemotherapy // Sci. Rep. 2017. Vol. 7. ID 45194.
89. Abe T., Nakata K., Kibe S. et al. Prognostic value of preoperative nutritional and immunological factors in patients with pancreatic ductal adenocarcinoma // Ann. Surg. Oncol. 2018. Vol. 25. № 13. P. 3996–4003.
90. Li H., Tian X., Xu Y. et al. Prognostic value of pre-treatment peripheral blood markers in pancreatic ductal adenocarcinoma and their association with S100A4 expression in tumor tissue // Oncol. Lett. 2019. Vol. 18. № 5. P. 4523–4534.
91. Kawai M., Hirono S., Okada K.I. et al. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer // Surgery. 2019. Vol. 165. № 6. P. 1151–1160.
92. Yang H.M., Lou G. The relationship of preoperative lymphocyte-monocyte ratio and the clinicopathological characteristics and prognosis of patients with epithelial ovarian cancer // Zhonghua Zhong Liu Za Zhi. 2017. Vol. 39. № 9. P. 676–680.
93. Kwon B.S., Jeong D.H., Byun J.M. et al. Prognostic value of preoperative lymphocyte-monocyte ratio in patients with ovarian clear cell carcinoma // J. Cancer. 2018. Vol. 9. № 7. P. 1127–1134.
94. Kwon B.S., Lee H.J., Yang J. et al. Prognostic value of preoperative lymphocyte-monocyte ratio in elderly patients with advanced epithelial ovarian cancer // Obstet. Gynecol. Sci. 2017. Vol. 60. № 6. P. 558–564.
95. Teck Seo S., Singh V.A., Yasin N.F. Preoperative lymphocyte count in relation to sarcoma prognosis // J. Orthop. Surg. (Hong Kong). 2019. Vol. 27. № 2. P. 2309499019854957.
96. Peng D., Gong Y.Q., Hao H. et al. Preoperative prognostic nutritional index is a significant predictor of survival with bladder cancer after radical cystectomy: a retrospective study // BMC Cancer. 2017. Vol. 17. № 1. P. 391.
97. Yoshida T., Kinoshita H., Yoshida K. et al. A novel risk stratification model, involving preoperative lymphocyte-monocyte ratio and standard pathological factors, for overall survival in patients with bladder cancer undergoing radical cystectomy // Jpn. J. Clin. Oncol. 2015. Vol. 45. № 12. P. 1162–1167.
98. Hutterer G.C., Sobolev N., Ehrlich G.C. et al. Pretreatment lymphocyte-monocyte ratio as a potential prognostic factor in a cohort of patients with upper tract urothelial carcinoma // J. Clin. Pathol. 2015. Vol. 68. № 5. P. 351–355.
99. Yoshida T., Kinoshita H., Yoshida K. et al. Prognostic impact of perioperative lymphocyte-monocyte ratio in patients with bladder cancer undergoing radical cystectomy // Tumour Biol. 2016. Vol. 37. № 8. P. 10067–10074.
100. Altan M., Haberal H.B., Akdogan B. et al. A critical prognostic analysis of neutrophil-lymphocyte ratio for patients undergoing nephroureterectomy due to upper urinary tract urothelial carcinoma // Int. J. Clin. Oncol. 2017. Vol. 22. № 5. P. 964–971.
101. Zhang G.M., Zhu Y., Luo L. et al. Preoperative lymphocyte-monocyte and platelet-lymphocyte ratios as predictors of overall survival in patients with bladder cancer undergoing radical cystectomy // Tumour Biol. 2015. Vol. 36. № 11. P. 8537–8543.
102. Bruix J., Cheng A.L., Meinhardt G. et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies // J. Hepatol. 2017. Vol. 67. № 5. P. 999–1008.
103. Wei K., Wang M., Zhang W. et al. Neutrophil-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with sorafenib // Med. Oncol. 2014. Vol. 31. № 6. P. 969.
104. Zhang W., Zhao G., Wei K. et al. Adjuvant sorafenib therapy in patients with resected hepatocellular carcinoma: evaluation of predictive factors // Med. Oncol. 2015. Vol. 32. № 4. P. 107.
105. Dell'Aquila E., Cremolini C., Zeppola T. et al. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO // Ann. Oncol. 2018. Vol. 29. № 4. P. 924–930.
106. Passardi A., Scarpi E., Cavanna L. et al. Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer // Oncotarget. 2016. Vol. 7. № 22. P. 33210–33219.
107. Ying H.Q., Deng Q.W., He B.S. et al. The prognostic value of preoperative NLR, d-NLR, PLR and LMR for predicting clinical outcome in surgical colorectal cancer patients // Med. Oncol. 2014. Vol. 31. № 12. P. 305.
108. Zhan X., Sun X., Hong Y. et al. Combined detection of preoperative neutrophil-to-lymphocyte ratio and CEA as an independent prognostic factor in nonmetastatic patients undergoing colorectal cancer resection is superior to NLR or CEA alone // Biomed. Res. Int. 2017.
109. Bong T.S.H., Tan G.H.C., Chia C. et al. Preoperative platelet-lymphocyte ratio is an independent prognostic marker and superior to carcinoembryonic antigen in colorectal peritoneal carcinomatosis patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy // Int. J. Clin. Oncol. 2017. Vol. 22. № 3. P. 511–518.
110. Котова З.С., Новик А.В., Юрлов Д.О. и др. Оценка прогностического и предиктивного значения нейтрофильно-лимфоцитарного индекса (НЛИ) у больных метастатическим колоректальным раком (КРР) // Сб. тезисов V Петербургского международного онкологического форума «Белые ночи 2019». 2019. С. 342.
111. Zaragoza J., Caille A., Beneton N. et al. High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma // Br. J. Dermatol. 2016. Vol. 174. № 1. P. 146–151.
112. Nakamura K., Yoshida N., Baba Y. et al. Elevated preoperative neutrophil-to-lymphocytes ratio predicts poor prognosis after esophagectomy in T1 esophageal cancer // Int. J. Clin. Oncol. 2017. Vol. 22. № 3. P. 469–475.
113. Templeton A.J., Knox J.J., Lin X. et al. Change in neutrophil-to-lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma as a prognosticator and biomarker of efficacy // Eur. Urol. 2016. Vol. 70. № 2. P. 358–364.
114. Kobayashi M., Kubo T., Komatsu K. et al. Changes in peripheral blood immune cells: their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapy // Med. Oncol. 2013. Vol. 30. № 2. P. 556.
115. el Aziz L.M. Blood neutrophil-lymphocyte ratio predicts survival in locally advanced cancer stomach treated with neoadjuvant chemotherapy FOLFOX 4 // Med. Oncol. 2014. Vol. 31. № 12. P. 311.
116. Asano Y., Kashiwagi S., Onoda N. et al. Predictive value of neutrophil/lymphocyte ratio for efficacy of preoperative chemotherapy in triple-negative breast cancer // Ann. Surg. Oncol. 2016. Vol. 23. № 4. P. 1104–1110.
117. Vernieri C., Mennitto A., Prisciandaro M. et al. The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer // Sci. Rep. 2018. Vol. 8. № 1. P. 8703.
118. Mehra N., Sharp A., Lorente D. et al. Neutrophil to lymphocyte ratio in castration-resistant prostate cancer patients treated with daily oral corticosteroids // Clin. Genitourin. Cancer. 2017. Vol. 15. № 6. P. 678–684.e671.
119. Guan B., Cao Z.P., Peng D. et al. Prognostic factors of patients with T2N0M0 upper tract urothelial carcinoma: a single-center retrospective study of 235 patients // Beijing Da Xue Xue Bao Yi Xue Ban. 2017. Vol. 49. № 4. P. 603–607.
120. Ojerholm E., Smith A., Hwang W.T. et al. Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: assessing prognostic and predictive value in SWOG 8710 // Cancer. 2017. Vol. 123. № 5. P. 794–801.
121. Riemann D., Cwikowski M., Turzer S. et al. Blood immune cell biomarkers in lung cancer // Clin. Exp. Immunol. 2019. Vol. 195. № 2. P. 179–189.
122. Grenader T., Nash S., Adams R. et al. Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study // Br. J. Cancer. 2016. Vol. 114. № 6. P. 612–615.
123. Grenader T., Nash S., Plotkin Y. et al. Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies // Ann. Oncol. 2015. Vol. 26. № 9. P. 1910–1916.
124. Gousias K., Markou M., Arzoglou V. et al. Frequent abnormalities of the immune system in gliomas and correlation with the WHO grading system of malignancy // J. Neuroimmunol. 2010. Vol. 226. № 1–2. P. 136–142.
125. Мишинов С.В., Леплина О.Ю., Тыринова Т.В. и др. Иммунологические показатели как потенциальные маркеры злокачественности опухолевых клеток и выживаемости пациентов при супратенториальных глиомах головного мозга // Российский нейрохирургический журнал им. профессора А.Л. Поленова. 2012. Т. 4. № 1. P. 29–35.
126. Личиницер М.Р., Абрамов М.Е., Кадагидзе З.Г. и др. Рефнот® – новый иммуномодулятор для лечения онкологических больных // Фарматека. 2013. № 17 (270). С. 30–33.
127. Andersen B.L., Farrar W.B., Golden-Kreutz D.M. et al. Psychological, behavioral, and immune changes after a psychological intervention: a clinical trial // J. Clin. Oncol. 2004. Vol. 22. № 17. P. 3570–3580.
128. Wang H., Liu H., Su W. et al. Relationship between CD4(+)CD25(High)CD127(low) regularly T cells in the peripheral blood and tumor regression after neoadjuvant therapy in patients with rectal cancer // Zhonghua Wei Chang Wai Ke Za Zhi. 2015. Vol. 18. № 4. P. 361–364.
129. Neagu M., Constantin C., Zurac S. Immune parameters in the prognosis and therapy monitoring of cutaneous melanoma patients: experience, role, and limitations // Biomed. Res. Int. 2013.
130. Кадагидзе З.Г., Черткова А.И., Заботина Т.Н. и др. Основные субпопуляции регуляторных лимфоцитов у больных злокачественной меланомой и раком молочной железы // Иммунология. 2014. Vol. 35. № 2. P. 64–67.
131. Hu F.J., Ge M.H., Li P. et al. Unfavorable clinical implications of circulating CD44+ lymphocytes in patients with nasopharyngeal carcinoma undergoing radiochemotherapy // Clin. Chim. Acta. 2012. Vol. 413. № 1–2. P. 213–218.
132. Skachkova O.V., Khranovska N.M., Gorbach O.I. et al. Immunological markers of anti-tumor dendritic cells vaccine efficiency in patients with non-small cell lung cancer // Exp. Oncol. 2013. Vol. 35. № 2. P. 109–113.
133. Mazzaschi G., Facchinetti F., Missale G. et al. The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC // Lung Cancer. 2019. Vol. 127. P. 153–163.
134. Гранов А.М., Молчанов О.Е., Карелин М.И. и др. Влияние иммунологических параметров на эффективность системной и локорегионарной иммунотерапии больных диссеминированным раком почки // Вопросы онкологии. 2009. Т. 55. № 5. С. 580–585.
135. Farace F., Pallardy M., Angevin E. et al. Metastatic renal-cell carcinoma patients treated with interleukin 2 or interleukin 2 plus interferon gamma: immunological monitoring // Int. J. Cancer. 1994. Vol. 57. № 6. P. 814–821.
136. Nakamura H., Kawasaki N., Hagiwara M. et al. Cellular immunologic parameters related to age, gender, and stage in lung cancer patients // Lung Cancer. 2000. Vol. 28. № 2. P. 139–145.
137. Неродо Г.А., Златник Е.Ю., Неродо Е.А. и др. Состояние иммунной системы как прогностический фактор у больных раком вульвы // Международный журнал экспериментального образования. 2013. № 11–1. С. 42–45.
138. Wolf G.T., Bradford C.R., Urba S. et al. Immune reactivity does not predict chemotherapy response, organ preservation, or survival in advanced laryngeal cancer // Laryngoscope. 2002. Vol. 112. № 8. Pt. 1. P. 1351–1356.
139. Yu Q.M., Yu C.D., Ling Z.Q. Elevated circulating CD19+ lymphocytes predict survival advantage in patients with gastric cancer // Asian Pac. J. Cancer Prev. 2012. Vol. 13. № 5. P. 2219–2224.
140. Барсуков В.Ю., Плохов В.Н., Чеснокова Н.П. и др. Закономерности нарушений активности клеточного звена иммунитета в динамике заболевания раком молочной железы // Вестник Волгоградского государственного медицинского университета. 2007. № 1 (21). С. 47–51.
141. Murta E.F., de Andrade J.M., Falcao R.P. et al. Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy // Tumori. 2000. Vol. 86. № 5. P. 403–407.
142. Soygur T., Beduk Y., Yaman O. et al. Analysis of the peripheral blood lymphocyte subsets in patients with bladder carcinoma // Urology. 1999. Vol. 53. № 1. P. 88–91.
143. Soygur T., Beduk Y., Baltaci S. et al. The prognostic value of peripheral blood lymphocyte subsets in patients with bladder carcinoma treated using neoadjuvant M-VEC chemotherapy // BJU Int. 1999. Vol. 84. № 9. P. 1069–1072.
144. Cantiello F., Russo G.I., Vartolomei M.D. et al. Systemic inflammatory markers and oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer // Eur. Urol. Oncol. 2018. Vol. 1. № 5. P. 403–410.
145. Sun X., Liu X., Liu J. et al. Preoperative neutrophil-to-lymphocyte ratio plus platelet-to-lymphocyte ratio in predicting survival for patients with stage I–II gastric cancer // Chin. J. Cancer. 2016. Vol. 35. № 1. P. 57.